Targeted
 Protein
Degradation

[ News ]

2020.10.01
An interview about UBIENCE was published in the October 1, 2020 issue of AnswersNews.
2020.09.11
An article about UBiENCE was published in the The Chemical Daily issued on September 11, 2020.
2020.08.26
An article about UBiENCE was published in the Nikkei Money Special Report in Nihon Keizai Shimbun issued on August 26, 2020.
2020.08.10
An article about UBiENCE was published on the column of "Venture tanbou" in Nikkei Biotechnology and Business issued on August 10, 2020.
2019.11.15
UBiENCE has been selected for the second phase of the Ministry of Economy, Trade and Industry's Intellectual Property Acceleration Program for 2019.
2019.10.16
UBiENCE Announces Collaboration Research Agreement With D. Western Therapeutics Institute for Ophthalmology.
2018.09.13
UBiENCE is adopted by ACT-MS along with National Institute of Health Sciences and Eisai.

Our Science

SNIPER: Specific and Non-genetic IAP-dependent Protein ERaser

IAPs are frequently overexpressed in tumor cells,
which is involved in resistance to tumor therapy

Company Overview

Name
UBiENCE Inc.
Address
8F Ueno Bldg. 1-9-10 Nihonbashi-horidomecho, Chuo-ku, Tokyo 103-0012, JAPAN
Business Summary
Discovery and Development of Pharmaceutical Compounds
Established
April 20, 2018
Capitalization
6,000,000Yen
Employees
3
Board of Directors
President Hirobumi TAKEUCHI
URL
https://www.ubience.com/
Fiscal Year
December

Hirobumi TAKEUCHI

President, Co-Founder

Hiro is the specialist in finance, accounting, and investor relation in the biotechnological field. He brings more than sixteen years of biotechnology industry experience, most recently serving five years as financial executive director of RaQualia Pharma. He successively held the position of Cyfuse Biomedical of Chief Administration Officer and Skylight Biotech of Chief Financial Officer. He founded UBiENCE in 2018.